Literature DB >> 26747019

A PK-PD model-based assessment of sugammadex effects on coagulation parameters.

Rolien Bosch1, Marie-José van Lierop2, Pieter-Jan de Kam3, Annelieke C Kruithof4, Jacobus Burggraaf4, Rik de Greef2, Sandra A G Visser5, Amy O Johnson-Levonas6, Huub-Jan Kleijn2.   

Abstract

Exposure-response analyses of sugammadex on activated partial thromboplastin time (APTT) and prothrombin time international normalized ratio (PT(INR)) were performed using data from two clinical trials in which subjects were co-treated with anti-coagulants, providing a framework to predict these responses in surgical patients on thromboprophylactic doses of low molecular weight or unfractionated heparin. Sugammadex-mediated increases in APTT and PT(INR) were described with a direct effect model, and this relationship was similar in the presence or absence of anti-coagulant therapy in either healthy volunteers or surgical patients. In surgical patients on thromboprophylactic therapy, model-based predictions showed 13.1% and 22.3% increases in respectively APTT and PT(INR) within 30min after administration of 16mg/kg sugammadex. These increases remain below thresholds seen following treatment with standard anti-coagulant therapy and were predicted to be short-lived paralleling the rapid decline in sugammadex plasma concentrations.
Copyright © 2016 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  APTT; PK–PD model; PT(INR); Pharmacodynamics; Pharmacokinetics; Sugammadex

Mesh:

Substances:

Year:  2015        PMID: 26747019     DOI: 10.1016/j.ejps.2015.12.028

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  1 in total

1.  Effects of Sugammadex versus Neostigmine on Intraoperative Coagulation Profiles in Patients with Thyroidectomy.

Authors:  Dizhou Zhao; Jieyu Fang; Wei Xiong; Jun Lin; Wanmei Chen; Chujun Wu
Journal:  Drug Des Devel Ther       Date:  2021-02-25       Impact factor: 4.162

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.